

Economic Evaluations of Targeted Therapy and Risk-stratified Treatment Approaches in Multiple Myeloma

Propositions

1. Variation in the prognosis, treatment, and costs of care is a hallmark of multiple myeloma. (*This thesis*)
2. Insight into treatment effectiveness in daily practice requires insight into the feasibility of outcomes research. (*This thesis*)
3. Early economic evaluations can identify if and when a hypothetical treatment will be both therapeutically and economically useful. (*This thesis*)
4. Use of molecular diagnostic techniques in risk-stratified multiple myeloma treatment can improve patient prognosis and be cost-saving. (*This thesis*)
5. Despite methodological differences, outcomes research and early economic evaluations in multiple myeloma are similar in different ways. (*This thesis*)
6. Measure what can be measured and make measurable what cannot be measured. (*Galileo Galilei*)
7. Essentially, all models are wrong, but some are useful. (*George E. Box*)
8. The way in which a physician uses biomarkers recapitulates an enduring practice of medicine: measure the patient, think about the result, and make a decision. (*Aaron S. Kesselheim and Jason Karlawish, New England Journal of Medicine, June 2012*)
9. The future is here – it's just not evenly distributed. (*William Gibson*)
10. The key to good decision making is not knowledge. It is understanding. We are swimming in the former. We are desperately lacking in the latter. (*Malcolm Gladwell*)
11. In the midst of winter, I found there was, within me, an invincible summer. (*Albert Camus*)

Jennifer Gail Gaultney

